Abstract
The article presents the first case of disseminated mucormycosis caused by Lichtheimia ornata, as well as an overview of our register data and analysis of publications on mucormycosis caused by Lichtheimia spp. Main underlying conditions in our patients with Lichtheimia mucormycosis were hematological malignancies (83%). Main risk factor was prolonged (median -47 days) severe neutropenia (72%), and steroids were used relatively rarely (55%). Lichtheimia mucormycosis was severe disease with ≥ 2 organs involvement in 66% patients. Combination therapy (lipid forms amphotericin B with echinocandins) and surgical treatment were often used for the treatment of Lichtheimia mucormycosis. The 12-weeks overall survival rate of patients with Lichtheimia mucormycosis was 44%.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Open Access Journal of Mycology & Mycological Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
